Literature DB >> 26721587

Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Jon B Toledo1, Pallavi Gopal2, Kevin Raible2, David J Irwin2,3, Johannes Brettschneider2,4, Samantha Sedor2, Kayla Waits2, Susana Boluda2, Murray Grossman3, Vivianna M Van Deerlin2, Edward B Lee2, Steven E Arnold3,5, John E Duda6, Howard Hurtig3, Virginia M-Y Lee2, Charles H Adler7, Thomas G Beach8, John Q Trojanowski2.   

Abstract

We investigated the distribution patterns of Lewy body-related pathology (LRP) and the effect of coincident Alzheimer disease (AD) pathology using a data-driven clustering approach that identified groups with different LRP pathology distributions without any diagnostic or researcher's input in two cohorts including: Parkinson disease patients without (PD, n = 141) and with AD (PD-AD, n = 80), dementia with Lewy bodies subjects without AD (DLB, n = 13) and demented subjects with AD and LRP pathology (Dem-AD-LB, n = 308). The Dem-AD-LB group presented two LRP patterns, olfactory-amygdala and limbic LRP with negligible brainstem pathology, that were absent in the PD groups, which are not currently included in the DLB staging system and lacked extracranial LRP as opposed to the PD group. The Dem-AD-LB individuals showed relative preservation of substantia nigra cells and dopamine active transporter in putamen. PD cases with AD pathology showed increased LRP. The cluster with occipital LRP was associated with non-AD type dementia clinical diagnosis in the Dem-AD-LB group and a faster progression to dementia in the PD groups. We found that (1) LRP pathology in Dem-AD-LB shows a distribution that differs from PD, without significant brainstem or extracranial LRP in initial phases; (2) coincident AD pathology is associated with increased LRP in PD indicating an interaction; (3) LRP and coincident AD pathology independently predict progression to dementia in PD, and (4) evaluation of LRP needs to acknowledge different LRP spreading patterns and evaluate substantia nigra integrity in the neuropathological assessment and consider the implications of neuropathological heterogeneity for clinical and biomarker characterization.

Entities:  

Keywords:  Alzheimer disease; Classification; Dementia with Lewy bodies; Diagnosis; Neuropathology; Parkinson disease

Mesh:

Substances:

Year:  2015        PMID: 26721587      PMCID: PMC4754135          DOI: 10.1007/s00401-015-1526-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  47 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice.

Authors:  Götz Heilbronner; Yvonne S Eisele; Franziska Langer; Stephan A Kaeser; Renata Novotny; Amudha Nagarathinam; Andreas Aslund; Per Hammarström; K Peter R Nilsson; Mathias Jucker
Journal:  EMBO Rep       Date:  2013-09-03       Impact factor: 8.807

3.  Distinct α-synuclein strains differentially promote tau inclusions in neurons.

Authors:  Jing L Guo; Dustin J Covell; Joshua P Daniels; Michiyo Iba; Anna Stieber; Bin Zhang; Dawn M Riddle; Linda K Kwong; Yan Xu; John Q Trojanowski; Virginia M Y Lee
Journal:  Cell       Date:  2013-07-03       Impact factor: 41.582

4.  CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.

Authors:  Jon B Toledo; Johannes Brettschneider; Murray Grossman; Steven E Arnold; William T Hu; Sharon X Xie; Virginia M-Y Lee; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-04-22       Impact factor: 17.088

5.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

6.  Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue.

Authors:  Jun-Xia Lu; Wei Qiang; Wai-Ming Yau; Charles D Schwieters; Stephen C Meredith; Robert Tycko
Journal:  Cell       Date:  2013-09-12       Impact factor: 41.582

7.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.

Authors:  Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-24       Impact factor: 21.566

8.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

9.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Authors:  Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski
Journal:  Acta Neuropathol Commun       Date:  2013-10-09       Impact factor: 7.801

Review 10.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

View more
  65 in total

Review 1.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

Review 2.  Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review.

Authors:  Garrett S Gibbons; Virginia M Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2019-01-01       Impact factor: 18.302

3.  MicroRNA expression patterns in human anterior cingulate and motor cortex: A study of dementia with Lewy bodies cases and controls.

Authors:  Peter T Nelson; Wang-Xia Wang; Sarah A Janse; Katherine L Thompson
Journal:  Brain Res       Date:  2017-11-13       Impact factor: 3.252

Review 4.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

Review 5.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

6.  Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.

Authors:  Aoyan Dong; Jon B Toledo; Nicolas Honnorat; Jimit Doshi; Erdem Varol; Aristeidis Sotiras; David Wolk; John Q Trojanowski; Christos Davatzikos
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

Review 7.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 8.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

9.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

10.  Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports.

Authors:  Jason W Adams; Victor E Alvarez; Jesse Mez; Bertrand R Huber; Yorghos Tripodis; Weiming Xia; Gaoyuan Meng; Caroline A Kubilus; Kerry Cormier; Patrick T Kiernan; Daniel H Daneshvar; Alicia S Chua; Sarah Svirsky; Raymond Nicks; Bobak Abdolmohammadi; Laney Evers; Todd M Solomon; Jonathan D Cherry; Nurgul Aytan; Ian Mahar; Sherral Devine; Sanford Auerbach; Michael L Alosco; Christopher J Nowinski; Neil W Kowall; Lee E Goldstein; Brigid Dwyer; Douglas I Katz; Robert C Cantu; Robert A Stern; Rhoda Au; Ann C McKee; Thor D Stein
Journal:  J Neuropathol Exp Neurol       Date:  2018-09-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.